Background Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC)
has improved pathological responses and survival rates compared with chemotherapy …

The clinical outcome of resectable non–small‐cell lung cancer (NSCLC) patients receiving
neoadjuvant chemoimmunotherapy is good but varies greatly. In addition, the pathological …

Background The association of early changes in the immune infiltrate during neoadjuvant
chemotherapy (NACT) with pathological complete response (pCR) in triple-negative breast …

Background Immunotherapy has revolutionized cancer treatment, but most patients are
refractory to immunotherapy or acquire resistance, with the underlying mechanisms …

Background Neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer
(NSCLC) represents an important research topic. Despite the potential benefits of this …

The use of immune checkpoint inhibitors (ICIs) has become mainstream in the treatment of
non–small-cell lung cancer (NSCLC). The idea of harnessing the immune system to fight …

8521 Background: The combination of chemotherapy and immunotherapy (CT-IO) has a
high response rate and longer survival in unselected patients (pts) with metastatic non-small …

Simple Summary Recently, the US Food and Drug Administration (FDA) approved
neoadjuvant immunotherapy plus chemotherapy for the treatment of resectable non-small …

Background There is a paucity of biomarkers that can predict the degree of pathological
response [eg, pathological complete response (pCR) or major response (pMR)] to …

Background Patients with locally advanced (stage III) non-small cell lung cancer (NSCLC)
demonstrate broad anatomic heterogeneity with modest survival benefits. Immune …